Cartography Biosciences

Cartography Biosciences is a private, clinical-stage biotech founded in 2021 and based in San Francisco. The company has developed a proprietary technology platform that creates detailed maps of antigen expression across millions of cells from thousands of patient samples, aiming to overcome the target limitation in immuno-oncology. With a lead T-cell engager program (CBI-1214) now in Phase 1 trials for colorectal cancer and a strategic collaboration with Pfizer, Cartography is advancing a pipeline of antibody-based therapies. The company is backed by significant venture capital, including a $67 million Series B financing round.

Proprietary platform integrating single-cell genomics, proteomics, and novel binder discovery to create a comprehensive antigen atlas. It maps antigen expression across millions of normal and cancerous cells to identify targets with optimal specificity, breadth, and safety profiles for immunotherapy development.

Cartography competes in the crowded target discovery space, facing competition from large pharma internal efforts and biotechs using genomics, proteomics, and AI/ML for novel antigen identification. Its differentiation lies in the unprecedented scale and resolution of its single-cell antigen atlas and its focus on directly profiling the therapeutic window for immunotherapy targets.